Is breast cancer survival improving? Trends in survival for patients with recurrent breast cancer diagnosed from 1974 through 2000

被引:387
作者
Giordano, SH
Buzdar, AU
Smith, TL
Kau, SW
Yang, Y
Hortobagyi, GN
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX USA
关键词
breast cancer; survival; prognostic factors; recurrence;
D O I
10.1002/cncr.11859
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Despite advances in therapies for breast cancer, improvement in survival for patients with recurrent or metastatic breast cancer has been difficult to establish. The objective of the current study was to determine whether the survival of women with recurrent breast cancer has improved from 1974 to 2000. METHODS. The authors analyzed the survival experience of 834 women who developed recurrent breast cancer between November 1974 and December 2000. All patients had been treated previously with adjuvant anthracycline-based protocols. Patients were divided into five consecutive groups based on year of breast cancer recurrence, and survival was compared across the five groups. Because some prognostic variables were divided unevenly divided among the cohorts, a multivariate model was created to determine the association of year of recurrence and survival after accounting for other prognostic factors. RESULTS. in the unadjusted analysis, there was a statistically significant improvement in survival across the five groups, and the more recent cohorts had longer survival (P < 0.001). Other variables that predicted longer survival after breast cancer recurrence included smaller initial tumor size, lower stage of disease, fewer lymph nodes involved, longer disease-free interval, estrogen receptor-positive tumors, and nonvisceral dominant site of disease recurrence. In the multivariate analysis, which adjusted for these prognostic factors, year of recurrence was associated with a trend toward improved survival, with a 1% reduction in risk for each increasing year. CONCLUSIONS. For these cohorts of patients, the authors present data suggesting that the prognosis for patients with recurrent breast cancer improved between 1974 and 2000. (C) 2003 American Cancer Society.
引用
收藏
页码:44 / 52
页数:9
相关论文
共 21 条
[11]   ADJUVANT THERAPY WITH ESCALATING DOSES OF DOXORUBICIN AND CYCLOPHOSPHAMIDE WITH OR WITHOUT LEUKOCYTE ALPHA-INTERFERON FOR STAGE-II OR STAGE-III BREAST-CANCER [J].
BUZDAR, AU ;
HORTOBAGYI, GN ;
KAU, SWC ;
SMITH, TL ;
FRASCHINI, G ;
HOLMES, FA ;
GUTTERMAN, JU ;
HUG, VM ;
SINGLETARY, SE ;
AMES, FC ;
MCNEESE, MD .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (10) :1540-1546
[12]  
CHIA SK, 2003, P AN M AM SOC CLIN, V22, pA22
[13]   SURVIVAL FROM 1ST RECURRENCE - RELATIVE IMPORTANCE OF PROGNOSTIC FACTORS IN 1,015 BREAST-CANCER PATIENTS [J].
CLARK, GM ;
SLEDGE, GW ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (01) :55-61
[14]  
COX DR, 1972, J R STAT SOC B, V34, P187
[15]   1-PHENYLALANINE MUSTARD (L-PAM) IN MANAGEMENT OF PRIMARY BREAST-CANCER - REPORT OF EARLY FINDINGS [J].
FISHER, B ;
CARBONE, P ;
ECONOMOU, SG ;
FRELICK, R ;
GLASS, A ;
LERNER, H ;
REDMOND, C ;
ZELEN, M ;
BAND, P ;
KATRYCH, DL ;
WOLMARK, N ;
FISHER, ER .
NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (03) :117-122
[16]   Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer [J].
Henderson, IC ;
Berry, DA ;
Demetri, GD ;
Cirrincione, CT ;
Goldstein, LJ ;
Martino, S ;
Ingle, JN ;
Cooper, MR ;
Hayes, DF ;
Tkaczuk, KH ;
Fleming, G ;
Holland, JF ;
Duggan, DB ;
Carpenter, JT ;
Frei, E ;
Schilsky, RL ;
Wood, WC ;
Muss, HB ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) :976-983
[17]   Cancer statistics, 2003 [J].
Jemal, A ;
Murray, T ;
Samuels, A ;
Ghafoor, A ;
Ward, E ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2003, 53 (01) :5-26
[18]   Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy [J].
Nabholtz, JM ;
Senn, HJ ;
Bezwoda, WR ;
Melnychuk, D ;
Deschênes, L ;
Douma, J ;
Vandenberg, TA ;
Rapoport, B ;
Rosso, R ;
Trillet-Lenoir, V ;
Drbal, J ;
Molino, A ;
Nortier, JWR ;
Richel, DJ ;
Nagykalnai, T ;
Siedlecki, P ;
Wilking, N ;
Genot, JY ;
Hupperets, PSGJ ;
Pannuti, F ;
Skarlos, D ;
Tomiak, EM ;
Murawsky, M ;
Alakl, M ;
Riva, A ;
Aapro, M .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1413-1424
[19]   Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results [J].
O'Shaughnessy, J ;
Miles, D ;
Vukelja, S ;
Moiseyenko, V ;
Ayoub, JP ;
Cervantes, G ;
Fumoleau, P ;
Jones, S ;
Lui, WY ;
Mauriac, L ;
Twelves, C ;
Van Hazel, G ;
Verma, S ;
Leonard, R .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (12) :2812-2823
[20]   Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].
Slamon, DJ ;
Leyland-Jones, B ;
Shak, S ;
Fuchs, H ;
Paton, V ;
Bajamonde, A ;
Fleming, T ;
Eiermann, W ;
Wolter, J ;
Pegram, M ;
Baselga, J ;
Norton, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792